These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18157559)

  • 1. The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments.
    Kobelt G; Jönsson B
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():95-106. PubMed ID: 18157559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The burden of rheumatoid arthritis and access to treatment: health burden and costs.
    Lundkvist J; Kastäng F; Kobelt G
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S49-60. PubMed ID: 18157732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The burden of rheumatoid arthritis and access to treatment: determinants of access.
    Lundqvist J; Kastäng F; Kobelt G; Jönsson B
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S87-93. PubMed ID: 18157560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis.
    Puolakka K; Kautiainen H; Mottonen T; Hannonen P; Korpela M; Hakala M; Luukkainen R; Vuori K; Blåfield H; Leirisalo-Repo M
    Scand J Rheumatol; 2009; 38(2):96-103. PubMed ID: 19274516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Sheffield rheumatoid arthritis health economic model.
    Tosh J; Brennan A; Wailoo A; Bansback N
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv26-31. PubMed ID: 21859702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based medicine is affordable: the cost-effectiveness of current compared with optimal treatment in rheumatoid and osteoarthritis.
    Andrews G; Simonella L; Lapsley H; Sanderson K; March L
    J Rheumatol; 2006 Apr; 33(4):671-80. PubMed ID: 16541479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient access to rheumatoid arthritis treatments.
    Jönsson B
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S35-8. PubMed ID: 18157679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis.
    Iannazzo S; De Francesco M; Gomez-Ulloa D; Benucci M
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):455-68. PubMed ID: 23977974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health services research in rheumatology: a great deal accomplished, a great deal left to do.
    Usman Iqbal S; Prashker M
    Rheum Dis Clin North Am; 2004 Nov; 30(4):879-98, viii. PubMed ID: 15488699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmö, Sweden.
    Jacobsson LT; Lindroth Y; Marsal L; Juran E; Bergström U; Kobelt G
    Scand J Rheumatol; 2007; 36(3):179-83. PubMed ID: 17657670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
    Polinski JM; Mohr PE; Johnson L
    Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic consequences of established rheumatoid arthritis and its treatment.
    Kavanaugh A
    Best Pract Res Clin Rheumatol; 2007 Oct; 21(5):929-42. PubMed ID: 17870036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advantages and limitations of utility assessment methods in rheumatoid arthritis.
    Beresniak A; Russell AS; Haraoui B; Bessette L; Bombardier C; Duru G
    J Rheumatol; 2007 Nov; 34(11):2193-200. PubMed ID: 17937471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The burden of rheumatoid arthritis: facts and figures.
    Callahan LF
    J Rheumatol Suppl; 1998 Jul; 53():8-12. PubMed ID: 9666412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.
    Sany J; Cohen JD; Combescure C; Bozonnat MC; Roch-Bras F; Lafon G; Daurès JP
    Rheumatology (Oxford); 2009 Oct; 48(10):1236-41. PubMed ID: 19620209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incremental cost effectiveness of in-patient versus out-patient rehabilitation after total hip arthroplasty - results of a pilot investigation.
    Krummenauer F; Günther KP; Witzlebf WC
    Eur J Med Res; 2008 Jun; 13(6):267-74. PubMed ID: 18558552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
    Khanna R; Smith MJ
    Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is early intervention worth it?
    Yelin E
    J Rheumatol Suppl; 2005 Jan; 72():36-8. PubMed ID: 15660464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
    Lindgren P; Geborek P; Kobelt G
    Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The burden of rheumatoid arthritis and access to treatment: a medical overview.
    Smolen J; Aletaha D
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S39-47. PubMed ID: 18157733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.